Ultragenyx Pharmaceutical (RARE) Cash from Operations (QoQ) (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) Cash from Operations (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.73 Bn | 2.32 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.34% |
| Dec 31, 2025 | -9.19% |
| Sep 30, 2025 | 15.93% |
| Jun 30, 2025 | 34.49% |
| Mar 31, 2025 | -109.29% |
| Dec 31, 2024 | -18.39% |
| Sep 30, 2024 | 12.95% |
| Jun 30, 2024 | 59.65% |
| Mar 31, 2024 | -126.79% |
| Dec 31, 2023 | 28.65% |
| Sep 30, 2023 | -1.47% |
| Jun 30, 2023 | 25.95% |
| Mar 31, 2023 | -73.64% |
| Dec 31, 2022 | 5.25% |
| Sep 30, 2022 | -23.41% |
| Jun 30, 2022 | 34.26% |
| Mar 31, 2022 | -116.25% |
| Dec 31, 2021 | 8.89% |
| Sep 30, 2021 | 8.73% |
| Jun 30, 2021 | 58.98% |